The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Novel CELMoDs: how may these agents fit into the myeloma treatment landscape?
In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on how the novel CELMoDs iberdomide and mezigdomide may fit into the myeloma treatment algorithm, highlighting their potent degradative ability and unique characteristics compared to IMiDs. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
